STOCK TITAN

Mesoblast Limited (MESO) furnishes ASX press release and investor deck

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Mesoblast Limited submitted a Form 6-K as a foreign private issuer for August 2025. The company furnished to U.S. investors an Australian Securities Exchange press release and an investor presentation dated August 29, 2025, attaching them as Exhibits 99.1 and 99.2 by reference.

Positive

  • None.

Negative

  • None.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the month of August 2025
Commission File Number 001-37626
Mesoblast Limited
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English)
Australia
(
Jurisdiction of incorporation or organization)

Silviu Itescu
Chief Executive Officer and Executive Director
Level 38
55 Collins Street
Melbourne 3000
Australia
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F Form 40-F





INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K
On August 29, 2025, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement and investor presentation, which are attached hereto as Exhibit 99.1 and Exhibit 99.2 and are incorporated herein by reference.






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited
/s/ Niva Sivakumar
Niva Sivakumar
Company Secretary
Dated: August 29, 2025



INDEX TO EXHIBITS
Item
99.1
Press release of Mesoblast Ltd, dated August 29, 2025.
99.2
Investor presentation of Mesoblast Ltd, dated August 29, 2025.




FAQ

What did Mesoblast Limited (MESO) report in its August 2025 Form 6-K?

Mesoblast Limited filed a Form 6-K to furnish an Australian Securities Exchange press release and an investor presentation dated August 29, 2025, which are attached as Exhibits 99.1 and 99.2 and incorporated by reference for U.S. investors.

Which documents are attached to Mesoblast (MESO) Form 6-K as exhibits?

The filing includes two exhibits: Exhibit 99.1 is a press release of Mesoblast Limited dated August 29, 2025, and Exhibit 99.2 is an investor presentation of Mesoblast Limited dated the same day, both filed previously with the Australian Securities Exchange.

Why did Mesoblast Limited (MESO) use Form 6-K in August 2025?

Mesoblast Limited used Form 6-K as a foreign private issuer to make its August 29, 2025 Australian Securities Exchange press release and investor presentation available in the United States by attaching them as exhibits and incorporating them by reference into the U.S. disclosure record.

Who signed the August 2025 Mesoblast Limited (MESO) Form 6-K?

The Form 6-K was signed on behalf of Mesoblast Limited by Company Secretary Niva Sivakumar. The signature block confirms that the registrant caused the report to be signed pursuant to the requirements of the Securities Exchange Act of 1934 on August 29, 2025.

What is the relationship between Mesoblast’s ASX filings and this Form 6-K?

On August 29, 2025, Mesoblast filed a news release and investor presentation with the Australian Securities Exchange. The Form 6-K furnishes those same documents to U.S. markets by attaching them as Exhibits 99.1 and 99.2 and incorporating them by reference.
Mesoblast

NASDAQ:MESO

View MESO Stock Overview

MESO Rankings

MESO Latest News

MESO Latest SEC Filings

MESO Stock Data

1.90B
122.32M
Biotechnology
Healthcare
Link
Australia
Melbourne